Novel Immunosuppression in Solid Organ Transplantation

Prasad Konda, Reshma Golamari, Howard J. Eisen

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

Solid organ transplantation and survival has improved tremendously in the last few decades, much of the success has been attributed to the advancements in immunosuppression. While steroids are being replaced and much of the immunosuppressive strategies focus on steroid free regimens, novel agents have introduced in the induction, maintenance, and treatment of acute rejection phase. MTOR inhibitors have helped with the renal sparing side effect from the calcineurin inhibitors, newer agents such as rituximab have decreased the incidence of donor-specific antibodies which led to decreased incidence of acute rejection reactions. In this chapter we discuss the newer therapies directed specifically for solid organ transplantation.

Original languageEnglish (US)
Title of host publicationHandbook of Experimental Pharmacology
PublisherSpringer Science and Business Media Deutschland GmbH
Pages267-285
Number of pages19
DOIs
StatePublished - 2022

Publication series

NameHandbook of Experimental Pharmacology
Volume272
ISSN (Print)0171-2004
ISSN (Electronic)1865-0325

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • General Pharmacology, Toxicology and Pharmaceutics

Fingerprint

Dive into the research topics of 'Novel Immunosuppression in Solid Organ Transplantation'. Together they form a unique fingerprint.

Cite this